MTNB

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 17

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,462

Underlying: Common Stock, par value $0.0001 per share · 141,462 shares

Expires not disclosed

F3 · date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern.

F3 · derivative.exercise_date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern.

F3 · derivative.expiration_date: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 16

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through A.K.S Family Partners LP

Disclosed balance after: 344,710

Underlying: Common Stock, par value $0.0001 per share · 344,710 shares

Expires not disclosed

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · derivative.exercise_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · derivative.expiration_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F4 · ownership.nature: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 15

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through A.K.S Family Partners LP

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · 344,710 shares

Expires 2030-04-08

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F4 · ownership.nature: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 14

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 630,335

Underlying: Common Stock, par value $0.0001 per share · 630,335 shares

Expires not disclosed

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · derivative.exercise_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · derivative.expiration_date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 13

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 0

Underlying: Common Stock, par value $0.0001 per share · 630,335 shares

Expires 2030-04-08

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 3

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 743,785

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 2

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through A.K.S Family Partners LP

Disclosed balance after: 416,900

F2 · date: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

SEC source: 0000921895-26-002105 · form413617016san_08132026.xml · derivative · entry 2

Sanitam Partners LLC · CIK 0002056830 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,798,636 shares

Expires 2030-04-08

F1 · kind: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant.

SEC source: 0000921895-26-002105 · form413617016san_08132026.xml · derivative · entry 1

Sanitam Partners LLC · CIK 0002056830 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,399,318 shares

Expires not disclosed

F1 · kind: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant.

F2 · derivative.expiration_date: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 12

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 630,335

Underlying: Common Stock, par value $0.0001 per share · 92,100 shares

Expires 2030-04-08

F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 113,450

F1 · date: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

F2 · price: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 11

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 265

Underlying: Common Stock, par value $0.0001 per share · 452,218 shares

Expires not disclosed

F5 · derivative.expiration_date: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.

F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

SEC source: 0000921895-26-002109 · form413617016ste_08132026.xml · derivative · entry 10

STERN ADAM K · CIK 0001403497 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern

Disclosed balance after: 800,000

Underlying: Common Stock, par value $0.0001 per share · 800,000 shares

Expires 2030-04-08

F1 · ownership.nature: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.

SEC source: 0001641172-25-008423 · ownership.xml · derivative · entry 1

D An Evelyn · CIK 0001325168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.

SEC source: 0001641172-25-008426 · ownership.xml · derivative · entry 1

NEUGEBOREN EDWARD · CIK 0001320873 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.

SEC source: 0001641172-25-008427 · ownership.xml · derivative · entry 1

Smith Robin L · CIK 0001365035 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.

SEC source: 0001641172-25-008425 · ownership.xml · derivative · entry 1

Murphy Keith · CIK 0001536583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.

SEC source: 0001641172-25-008424 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,100

Underlying: Common Stock · 70,100 shares

Expires 2035-04-30

F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026.

SEC source: 0001477932-25-002580 · form4a.xml · derivative · entry 2

Pembroke & Partners LLC · CIK 0002056785 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,358,364

Underlying: Common Stock · 1,679,182 shares

Expires 2030-04-08

F1 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.

SEC source: 0001477932-25-002580 · form4a.xml · derivative · entry 1

Pembroke & Partners LLC · CIK 0002056785 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 984

Underlying: Common Stock · 839,591 shares

Expires not disclosed

F1 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.

F3 · derivative.expiration_date: N/A

F2 · balance_after: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power based on the Preferred Stock of up to 23% of the outstanding Common Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.

SEC source: 0001477932-25-002594 · form4a.xml · derivative · entry 2

Sanitam Partners LLC · CIK 0002056830 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,798,636

Underlying: Common Stock · 2,399,318 shares

Expires 2030-04-08

F1 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants.

SEC source: 0001477932-25-002594 · form4a.xml · derivative · entry 1

Sanitam Partners LLC · CIK 0002056830 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,406

Underlying: Common Stock · 1,199,659 shares

Expires not disclosed

F1 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants.

F3 · derivative.expiration_date: N/A

F2 · balance_after: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Sanitam voting power from the Preferred Strock of up to 30.2% of the outstanding Common Stock. Sanitam's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.

SEC source: 0001477932-25-002583 · form4a.xml · derivative · entry 3

EIDE ROBERT J · CIK 0001181955 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · R. Eide as managing partner for Pembroke

Disclosed balance after: 3,358,364

Underlying: Common Stock · 1,679,182 shares

Expires 2030-04-08

F2 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.

F4 · ownership.nature: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power.

SEC source: 0001477932-25-002583 · form4a.xml · derivative · entry 2

EIDE ROBERT J · CIK 0001181955 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · R. Eide as managing partner for Pembroke

Disclosed balance after: 984

Underlying: Common Stock · 839,591 shares

Expires not disclosed

F2 · price: Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.

F5 · derivative.expiration_date: N/A

F3 · balance_after: Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.

F4 · ownership.nature: Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power.

SEC source: 0001493152-23-045169 · ownership.xml · derivative · entry 1

Hoover Thomas · CIK 0001898716 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-045167 · ownership.xml · derivative · entry 1

Matkovits Theresa · CIK 0001745393 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,300,000

Underlying: Common Stock · 1,300,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-045171 · ownership.xml · derivative · entry 1

Kucinski Keith A · CIK 0001763405 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-045172 · ownership.xml · derivative · entry 1

Liu Hui · CIK 0001834660 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-045170 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,500,000

Underlying: Common Stock · 3,500,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-045168 · ownership.xml · derivative · entry 1

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,200,000

Underlying: Common Stock · 1,200,000 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.

SEC source: 0001493152-23-039335 · ownership.xml · derivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-23-039339 · ownership.xml · derivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-23-039336 · ownership.xml · derivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-23-039340 · ownership.xml · derivative · entry 1

Giordano Natasha · CIK 0001315585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-23-039337 · ownership.xml · derivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-23-039338 · ownership.xml · derivative · entry 1

Corzo Kathryn Penkus · CIK 0001884123 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,244

Underlying: Common Stock · 437,244 shares

Expires 2033-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-036234 · ownership.xml · derivative · entry 1

Hoover Thomas · CIK 0001898716 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,000

Underlying: Common Stock · 475,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-036243 · ownership.xml · derivative · entry 1

Matkovits Theresa · CIK 0001745393 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,000

Underlying: Common Stock · 625,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-036240 · ownership.xml · derivative · entry 1

Liu Hui · CIK 0001834660 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,000

Underlying: Common Stock · 625,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-036238 · ownership.xml · derivative · entry 1

Kucinski Keith A · CIK 0001763405 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,000

Underlying: Common Stock · 625,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-036236 · ownership.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,988,300

Underlying: Common Stock · 1,988,300 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-036232 · ownership.xml · derivative · entry 1

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,000

Underlying: Common Stock · 625,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023.

SEC source: 0001493152-22-032690 · ownership.xml · derivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-032691 · ownership.xml · derivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-032692 · ownership.xml · derivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-032695 · ownership.xml · derivative · entry 1

Giordano Natasha · CIK 0001315585 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-032688 · ownership.xml · derivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-032694 · ownership.xml · derivative · entry 1

Corzo Kathryn Penkus · CIK 0001884123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,657

Underlying: Common Stock · 142,657 shares

Expires 2032-11-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 4

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees

Disclosed balance after: 4,694,566

SEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 3

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT)

Disclosed balance after: 0